IL6 and breast carcinoma: IL-17 can also induce the production of IL-6 and CCL20 in metastatic, but not in non-metastatic breast cancer tumor cells (23), thereby promoting inflammation and proliferation through IL-6 mediated STAT3 pathway activation (27).